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ABSTRACT
Objective: To determine the incremental cost-effectiveness of clopidogrel
plus aspirin (C + A) compared with aspirin (A) alone during the Clopi-
dogrel for High Atherothrombotic Risk and Ischemic Stabilization, Man-
agement and Avoidance (CHARISMA) trial from a US payer perspective.
Background: Although the CHARISMA trial did not ﬁnd a beneﬁt of
adding clopidogrel to aspirin in its overall study cohort, a beneﬁt was
suggested in a prespeciﬁed subgroup of patients with established cardio-
vascular (CV) disease. The cost-effectiveness of dual antiplatelet therapy in
this population is unknown.
Methods: Medical resource utilization was assessed prospectively, and
costs for hospitalizations, physician services, outpatient care, and medica-
tions were assigned using 2007 US dollars. Life expectancy was estimated
contingent on fatal and nonfatal CV events using statistical models of
long-term survival from the Saskatchewan Health database.
Results: C + A was associated with a 12.5% relative reduction in CV
death, myocardial infarction, or stroke compared with A alone (6.9% vs.
7.9%, P = 0.048) over a median 28 months of follow-up. Severe or mod-
erate bleeding events were higher in patients receiving C + A versus A
alone (3.6% vs. 2.5%, P < 0.001). Mean cost/patient was $2607 higher
for C + A, while projected life expectancy increased by an average of 0.072
years due to fewer in-trial events. The resulting incremental cost-
effectiveness ratio (ICER) for C + A was $36,343/year of life gained.
Findings were insensitive to discount rate, life expectancy projections,
post-event costs, and indirect costs from lost productivity; the ICER was
most sensitive to the cost of clopidogrel. Bootstrap analysis demonstrated
that the ICER for C + A remained <$50,000/life-year gained in 70.6% of
bootstrap replicates and <$100,000/life-year gained in 87.4%.
Conclusions: Among patients with established CV disease, adding clopi-
dogrel to aspirin appears to increase life expectancy modestly at a cost
generally considered acceptable within the US health-care system.
Keywords: aspirin, cardiovascular disease, clopidogrel, cost-effectiveness
analysis, secondary prevention.
Introduction
Although previous studies have established the beneﬁts of dual
antiplatelet therapy for short- and intermediate-term administra-
tion in the setting of acute coronary syndrome (ACS) and after
percutaneous coronary intervention (PCI) [1–3], the value of
treating a population with chronic cardiovascular (CV) disease at
high risk for new or recurrent events is less certain. The Clopi-
dogrel for High Atherothrombotic Risk and Ischemic Stabiliza-
tion, Management and Avoidance (CHARISMA) trial examined
this issue by evaluating the efﬁcacy of clopidogrel plus low-dose
aspirin compared with aspirin alone in a cohort of patients with
established CV disease or multiple risk factors for CV events.
Although the trial failed to demonstrate a beneﬁt of clopidogrel
for the primary composite end point of CV death, myocardial
infarction (MI), or stroke in the overall population, a beneﬁt was
found in the prespeciﬁed subgroup of patientswith establishedCV
disease [4]. A recent subgroup analysis of CHARISMA limited
to subjects with prior MI, ischemic stroke, or symptomatic peri-
pheral arterial disease (PAD) also demonstrated a signiﬁcant
reduction in the primary trial end point [5]. Given these ﬁndings,
dual antiplatelet therapy is often considered in patientswith a high
risk of atherothrombotic events—particularly those with exten-
sive CV disease [6].
Whether dual antiplatelet therapy should be prescribed rou-
tinely to such high-risk patient cohorts requires a complete
understanding of the long-term consequences of such therapy. In
particular, for an individual patient, this decision must consider
the trade-off between the potential beneﬁts of preventing
ischemic events weighed against the risk of bleeding complica-
tions. From a population perspective, the decision is further
complicated by the fact that clopidogrel is a costly drug, particu-
larly when given over an extended period.
During the design of CHARISMA, it was recognized that
economic considerations would play an important role in deter-
mining the appropriate role of dual antiplatelet therapy for long-
term prevention of atherothrombotic events and a prospective
economic evaluation was therefore developed alongside the
CHARISMA trial. Although the economic study was originally
designed to incorporate the full trial population, given the trial’s
results (in particular, the ﬁnding of overt harm among the
primary prevention subgroup), we felt that from both a clinical
and policy perspective, the most informative analysis would be
conﬁned to the subgroup of 12,153 patients with established CV
disease at the time of enrollment. The goal of the present study
were thus to assess the cost-effectiveness of adding clopidogrel to
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aspirin for subjects with established CV disease based on empiri-
cal data from the CHARISMA trial.
Methods
Design and Principal Findings of the CHARISMA Trial
The design and ﬁndings of the CHARISMA trial have been
reported previously [4,7]. Brieﬂy, CHARISMA was a multicenter
randomized controlled trial that examined whether clopidogrel
plus low-dose aspirin would reduce CV events compared with
low-dose aspirin alone among patients with either established
coronary, cerebrovascular, or PAD or with multiple risk factors
for CV events. Overall, 15,603 patients were recruited from 32
countries and 768 sites between October 1, 2002 and November
14, 2003 and were randomized to receive 75 mg of clopidogrel
daily or placebo over a median follow-up period of 28 months.
All patients received 75 to 162 mg of aspirin daily. Patients were
excluded from CHARISMA if they were considered to require
clopidogrel at the time of enrollment (e.g., due to recent PCI).
Nevertheless, if enrolled patients underwent coronary stenting
after randomization, they received open-label clopidogrel and
subsequent costs were captured. The CHARISMA trial demon-
strated a statistically signiﬁcant beneﬁt in the prespeciﬁed sub-
group of patients with established CV disease, with a 12.5%
relative reduction in the primary composite end point of CV
death, MI, or stroke compared with aspirin alone (6.9% vs.
7.9%, P = 0.048) [4]. Subjects randomized to clopidogrel were
also more likely to experience moderate-to-severe bleeding
(3.6% vs. 2.5%, P < 0.001).
Economic Analysis
The goal of the economic analysis was to evaluate the incremen-
tal cost and cost-effectiveness of clopidogrel and aspirin versus
aspirin alone in patients with established CV disease. The per-
spective of the economic analysis was that of the US health-care
system (payer perspective). Although the analysis considered a
lifetime horizon for each patient, the actual duration of treatment
was assumed to mirror that provided in CHARISMA (a median
of 28 months) because the precise effect of long-term therapy in
this population is unknown.
Cost Estimation
The general approach to estimating costs was to multiply counts
of resource utilization (hospitalizations, physician costs, proce-
dures, post-acute care, medications) by price weights derived
from comparable populations of US patients. The most recent
national cost data available at the time of analysis were used and
inﬂated to 2007 US dollars using the medical component of the
Consumer Price Index. All unit costs were deﬁned prospectively
and applied in a blinded fashion to all patients.
Life Expectancy Estimation
As noted previously, the median duration of follow-up observed
for an individual patient enrolled in CHARISMA was 28
months. Because the in-trial follow-up duration was relatively
brief compared with overall life expectancy for the CHARISMA
population, our analysis required the calculation of life expect-
ancy estimates for the study population to determine the years
of life lost due to both fatal and nonfatal events during the
trial. These estimates were derived from an analysis of the
Saskatchewan Health Database—a publicly available, compre-
hensive, longitudinal health-care utilization database containing
the entire population of the Canadian province of Saskatchewan
[8,9].
We identiﬁed a reference population with similar baseline
characteristics to CHARISMA subgroup with established CV
disease: a cohort of 53,983 men and women aged45 years with
hospital or clinic visit between 1990 and 1995 with diagnosis
codes indicating coronary artery disease (angina, MI, PCI, or
coronary artery bypass graft surgery), cerebrovascular disease
(ischemic stroke or transient ischemic attack [10]), or PAD.
Follow-up survival data for this cohort were available through
2002. Parametric regression models were developed to estimate
piecewise hazard functions of death over time for patients who
experienced nonfatal MI or stroke (or their combination), adjust-
ing for age, sex, key CV risk factors, and prior events/procedures;
and life expectancy for each study participant who survived to
the end of the study was predicted contingent on occurrence of
in-trial CV events [11]. Life expectancy projections were condi-
tional on the occurrence of combinations of MI and stroke
severity that were components of the primary composite end
point of the study. These projections accounted for the number of
days of survival already observed within the trial for each subject
by incorporating a mean delay derived from the average time
from the last qualifying event in the CHARISMA trial to the end
of the follow-up for patients alive at the end of the study.
Analyses from the Saskatchewan database have demonstrated
that such regression-based life expectancy predictions are com-
parable to and validated against results observed in other epide-
miologic studies of coronary artery disease [12]. Analogous
approaches have been used as a source for life expectancy pro-
jections for several previous trial-based economic analyses as
well [13–16]. Because we assumed that clopidogrel treatment
would be discontinued at the end of the trial, our base-case
analysis assumed no further differences between the two groups
in the rate of subsequent CV events beyond the end of the trial.
Statistical Analysis
Categorical data are reported as frequencies, and continuous
data are reported as mean  standard deviation. Categorical
variables were compared using the Fisher’s exact test, and con-
tinuous variables were compared using the two-sample t test for
means. All statistical calculations were performed using SAS
version 9 (SAS Institute, Cary, NC).
Cost-Effectiveness Analysis
The incremental cost-effectiveness ratio (ICER) of clopidogrel +
aspirin versus aspirin alone was calculated by dividing the net
cost associated with clopidogrel treatment by the difference in
lost life expectancy between the two treatment groups, where lost
life expectancy represents the difference between an individual’s
life expectancy based on the observed in-trial outcomes and his
or her life expectancy in the absence of primary outcome events.
For a patient who died during the study, lost life expectancy was
the difference between predicted life expectancy at the beginning
of the study and observed survival duration. For a patient who
experienced no adverse events during the trial, lost life expect-
ancy was zero. We used lost life expectancy (rather than differ-
ences in life expectancy) as the basis for our cost-effectiveness
analysis to minimize the chance that minor imbalances in the
baseline distribution of patient characteristics between treatment
groups would produce spurious results.
We used bootstrap resampling (1000 replicates) to calculate
bias-corrected 95% conﬁdence intervals for all costs and cost
differences. The probability that clopidogrel treatment would be
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economically attractive over a range of willingness-to-pay thresh-
olds was displayed in the form of a cost-effectiveness acceptabil-
ity curve [17]. Consistent with current guidelines, both costs and
life expectancy in the base-case were discounted 3% annually.
Sensitivity analyses were performed, varying each of the key
analytic assumptions, including the cost of clopidogrel, discount
rate, post-acute care costs, and estimates of lost life-years (LYs).
Indirect Cost Analysis
Although indirect costs were excluded from the primary eco-
nomic analysis, we conducted secondary analyses examining the
impact of indirect costs due to lost productivity on the cost-
effectiveness. Estimates of indirect costs and the proportion of
patients working were obtained from a 1-year follow-up data
from the Reduction of Atherothrombosis for Continued Health
Registry [6], pertaining to a cohort of patients similar to those
with established CV disease in CHARISMA. We estimated the
proportion of working individuals within risk groups deﬁned
according to patient history and the associated average number
of missed days of work associated with speciﬁc CV events (MI,
stroke, and combinations of MI and stroke). The costs associated
with lost productivity were then estimated by multiplying the
proportion of CHARISMA-eligible patients who were employed
(by age and sex) by the median daily wage for the United States
in 2004 [18] inﬂated to 2007 dollars ($139), and multiplied by
the mean number of missed work days associated with the spe-
ciﬁc event. A similar approach was used for days of work lost due
to a fatal event, except that a “friction cost” approach [19] was
used which capped duration of lost work at 96 days, beyond
which we assumed that a replacement for the deceased worker
would be found.
Role of the Sponsor
The CHARISMA trial and the associated economic evaluation
were funded by grants from Sanoﬁ-Aventis (Paris, France) and
Bristol-Myers Squibb (New York, NY). Although the analysis
plan was developed prospectively in conjunction with the CHA-
RISMA investigators and sponsors, the authors had free access to




Of the 12,153 subjects with established CV disease enrolled in
CHARISMA, 6062 were randomized to clopidogrel + aspirin,
and 6091 were randomized to aspirin alone. There were no
signiﬁcant differences in the baseline clinical characteristics
between the two groups (Table 1). Among the subgroup with
established CV disease, clopidogrel + aspirin was associated with
a reduction in the incidence of the primary composite end point
of CV death, MI, or stroke compared with aspirin alone (6.9%
vs. 7.9%, P = 0.048) [4]. Dual antiplatelet therapy was associ-
ated with trends toward lower risk for CV death, MI, and stroke
when examined individually—although none of these differences
reached statistical signiﬁcance (Table 1). Severe or moderate
bleeding events were higher in patients receiving clopidogrel +
aspirin compared with aspirin alone (3.6% vs. 2.5%, P < 0.001).
Medical Resource Utilization and Costs
Overall, there were no signiﬁcant differences in the incidence of
hospitalization during the 28-month follow-up period of patients
randomized to clopidogrel + aspirin compared with aspirin alone
(Table 2). Although the hospitalization rate for stroke or intrac-
ranial hemorrhage was signiﬁcantly lower with clopidogrel (2.5
vs. 3.4 per 100 patients, P = 0.01), this was counterbalanced by
an increase in the rate of hospitalization for bleeding (2.7 vs. 1.5
per 100 patients, P < 0.001). The rates of hospitalization for MI
or other CV reasons were not signiﬁcantly different between the
two treatment groups. No signiﬁcant differences in the rates of
coronary, cerebrovascular, or peripheral arterial revasculariza-
tion procedures were noted between the clopidogrel + aspirin
and aspirin alone groups.
Overall, medical care costs were $2607/patient higher for the
clopidogrel + aspirin group compared with the aspirin alone




(N = 6091) P-value
Age (years, standard deviation) 64.0 9.6 64.1 9.6 0.494
Female (%) 27.4 27.0 0.639
Diabetes (%) 31.1 31.0 0.875
Hypertension 69.0 70.3 0.124
Current smoker (%) 19.7 20.1 0.570
Prior myocardial infarction (%) 40.7 41.9 0.191
Prior stroke (%) 30.2 29.3 0.331
History of peripheral arterial disease (%) 26.3 26.4 0.902
Hypercholesterolemia (%) 71.3 71.7 0.574
Prior percutaneous coronary intervention (%) 26.5 27.0 0.525
Prior coronary artery bypass surgery (%) 22.3 22.7 0.664
Prior carotid endarterectomy (%) 5.6 5.2 0.355
Prior peripheral revascularization (%) 14.1 13.6 0.431
Primary efﬁcacy end point (cardiovascular death, MI, or stroke) (%) 6.9 7.9 0.048
Death from any cause (%) 4.6 5.0 0.27
Cardiovascular death (%) 2.8 3.1 0.34
MI—fatal and nonfatal (%) 2.4 2.7 0.28
Stroke—fatal and nonfatal (%) 2.8 3.3 0.09
Ischemic stroke (%) 2.4 2.8 0.14
Intracranial hemorrhage (%) 0.3 0.3 0.87
Severe or moderate bleeding (%) 3.6 2.5 <0.001
CV, cardiovascular; MI, myocardial infarction.
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group ($13,743 vs. $11,136, P < 0.001; Table 3). Higher medi-
cation costs over the study period explained virtually all of
this difference, with additional costs of $2894/patient for
clopidogrel + aspirin treatment compared with aspirin alone
($3062 vs. $169, P < 0.001). Other costs including hospitaliza-
tions, physician services, and outpatient/chronic care tended to
be less among the clopidogrel group, but these differences were
not statistically signiﬁcant.
Life Expectancy
Table 4 presents age and sex-speciﬁc life expectancy and lost life
expectancy values projected for prototypical CHARISMA par-
ticipants based on the Saskatchewan Health Database. For
example, for a 65-year-old man alive at the end of the trial, the
observed lost life expectancy due to a nonfatal MI was 4.7 years
and ranged from 6.2 to 8.7 years for a nonfatal stroke depending
on severity. As expected, younger patients had greater life expect-
ancy losses associated with in-trial events because of their longer
life spans compared with older patients. Women had greater lost
life expectancies than men for comparable event patterns.
Cost-effectiveness analysis: base-case. Under our baseline
assumptions, treatment with clopidogrel + aspirin over a median
of 28 months was projected to increase life expectancy by 0.072
years/patient compared with aspirin alone while increasing
medical care costs by $2607/patient. The resulting ICER for
clopidogrel was $36,343 per LY gained (Table 5). The clopi-
dogrel strategy was more costly in 100% of trial replicates and
economically dominated (i.e., more costly and less effective) in
5.4%. Under our base-case assumptions, the ICER for the addi-
tion of clopidogrel to aspirin was <$50,000 per LY gained in
70.6% of simulations and <$100,000 per LY gained in 87.4%
(Fig. 1).
Subgroup Analyses
In general, there was little variation in the incremental cost of
clopidogrel therapy across the subgroups examined. Female
patients had higher incremental costs associated with a dual
antiplatelet strategy ($3284) compared with men ($2360)
leading to a higher ICER ($54,817 vs. $31,024/LY gained). Pro-
jected gains in life expectancy among patient subgroups ranged
from a low of 0.040 years among patients aged 65 years to a
high of 0.133 years among patients with symptomatic PAD
(Table 4). As a result, the ICER for clopidogrel treatment was
<$25,000/LY gained among patients with previous CV events or
PAD, and substantially higher among patients without these
conditions. The cost-effectiveness of clopidogrel was also less
favorable among patients aged 65 years and diabetic patients,
primarily because of smaller predicted gains in life expectancy
compared with younger and nondiabetic patients.
Sensitivity Analyses
Clopidogrel remained economically attractive over a broad range
of assumptions regarding post-event costs, the prognostic impact
of nonfatal events, and discount rates (Table 6). Because the
majority of the cost difference between the two treatment arms
Table 2 Medical resource utilization and costs in the CHARISMA trial
Clopidogrel + Aspirin Aspirin alone Absolute difference (95% CI) P-value
Hospitalizations (N per 100 patients)
Total admissions 36.37 37.60 -1.22 (-4.21, 1.76) 0.42
MI admissions 2.54 2.89 -0.35 (-1.04, 0.34) 0.32
Stroke/ICH admissions 2.51 3.41 -0.91 (-1.58, -0.23) 0.01
Severe or moderate bleeding 2.74 1.46 1.28 (0.69, 1.86) <0.001
Other cardiovascular-related admissions* 28.59 29.83 -1.24 (-3.88, 1.39) 0.36
Total length of stay (days) 3.57 3.49 0.08 (-0.43, 0.58) 0.76
Cardiovascular resource use (N per 100 patients)
Coronary angiography 7.16 7.09 0.07 (-0.94, 1.07) 0.90
Balloon angioplasty 2.87 3.02 -0.15 (-0.81, 0.51) 0.65
PCI 4.32 4.76 -0.44 (-1.25, 0.38) 0.29
CABG 1.63 1.66 -0.03 (-0.48, 0.43) 0.91
Carotid endarterectomy 0.82 0.85 -0.03 (-0.36, 0.31) 0.87
Peripheral artery bypass 7.16 7.09 0.07 (-0.94, 1.07) 0.90
Mean cost per patient†
Hospitalizations $4,109 $4,266 –$157 (-534, 212) 0.42
Inpatient physician costs $1,329 $1,363 –$35 (-149, 76) 0.56
Clopidogrel $3,062 $169 $2,894 (2,861, 2,927) <0.001
Other medications $4,822 $4,837 –$16 (-117, 82) 0.77
Outpatient care $421 $501 –$80 (-173, 11) 0.08
Total $13,743 $11,136 $2,607 (2,068, 3,146) <0.001
*Includes unstable angina, transient ischemic attack or coronary revascularization.
†Reported costs are discounted by 3%. Conﬁdence intervals for costs estimated from bootstrap analysis of 1,000 replicates.The conﬁdence interval suggests that the parameter of interest is
within the stated range in 95% of replicates. Conﬁdence intervals that exclude zero suggest less than a 5% statistical signiﬁcance due to chance alone.
CABG, coronary artery bypass graft surgery; CHARISMA, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance; ICH, intracranial hemorrhage;
MI, myocardial infarction; PCI, percutaneous coronary intervention.
Table 3 Projected life expectancy and lost life expectancy associated












Male, age 55 15.04 5.74 8.72 11.79
Male, age 65 11.63 4.69 6.23 8.71
Male, age 75 8.28 3.31 4.03 5.9
Female, age 55 16.49 6.97 9.95 13.34
Female, age 65 13.17 5.93 7.53 10.34
Female, age 75 9.77 4.47 5.27 7.46
*Lost life expectancy represents the difference between an individual’s life expectancy
without events and his/her life expectancy conditional on experiencing an event of interest
during the trial period.
MI, myocardial infarction.
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was due to the cost of clopidogrel itself, the cost-effectiveness of
clopidogrel was particularly sensitive to its acquisition cost: a
50% decrease in the daily cost of clopidogrel resulted in an ICER
of $16,176/LY, whereas a 50% increase in cost resulted in an
ICER of $56,520/LY.
Secondary Analyses
Indirect costs associated with lost work productivity were esti-
mated to be $96 and $110 for the clopidogrel + aspirin and
aspirin alone groups, respectively. When these costs were
included in the analysis, the ICER for clopidogrel was
$36,148/LY gained. When we repeated our analysis using the
entire CHARISMA population (including patients with multiple
risk factors but no known CV disease at enrollment), the cost-
effectiveness ratio increased to $84,657/LY gained (incremental
cost = $2607; incremental life expectancy = 0.031 years).
Discussion
Although several studies have examined the cost-effectiveness of
clopidogrel for short-term administration after ACS or PCI
[15,20,21], this is the ﬁrst prospectively designed economic
evaluation of the addition of clopidogrel to contemporary
medical therapy (including aspirin) for secondary prevention
among patients with established CV disease. Based on the CHA-
RISMA results, treatment with clopidogrel over a median of 28
months was associated with an absolute 1% lower risk of CV
death, MI, or stroke at a net cost of $2607/patient. When
extended over a lifetime horizon, these clinical beneﬁts were
projected to increase average life expectancy by 0.072 years with
a resulting ICER of $36,343/LY gained—a value generally con-
sidered acceptable within the US health-care system. [22] Our
results were sensitive to the cost of clopidogrel but relatively
insensitive to most other analytic parameters including the dis-
count rate, the cost of inpatient and outpatient care, the cost of
bleeding events, and the prognostic impact of nonfatal events.
Although the overall CHARISMA trial enrolled patients with
both established CV disease and high-risk patients with multiple
risk factors, we restricted our economic analysis to the large
subgroup (>80% of the overall study population) with estab-
lished CV disease at enrollment—a population found to beneﬁt
from adjunctive clopidogrel [4]. There are several reasons for this
approach. First, this subgroup was prespeciﬁed in the analytic
plan, prospectively identiﬁed at the time of enrollment, and dif-
fered both qualitatively and quantitatively in its response to
Table 4 Cost-effectiveness among selected patient subgroups
Clopidogrel + Aspirin (N)
Aspirin





Overall population 6,062 6,091 $2,607 0.072 $36,343
Age <65 3,188 3,173 2,777 0.099 $28,144
Age 65 2,874 2,918 2,430 0.040 $61,213
Male 4,400 4,445 $2,360 0.076 $31,024
Female 1,662 1,646 $3,284 0.060 $54,817
Caucasian 5,533 5,567 $2,692 0.075 $36,139
Non-Caucasian 529 524 $1,721 0.043 $39,745
Diabetes mellitus 1,886 1,887 $2,428 0.057 $42,303
Without diabetes 4,176 4,204 $2,681 0.079 $34,024
Prior MI* 2,470 2,553 $2,662 0.130 $20,413
Prior stroke* 1,828 1,787 $2,558 0.121 $21,163
Documented PAD* 1,594 1,608 $1,450 0.133 $10,910
No prior MI, stroke, or PAD† 959 946 $3,570 0.079 $45,088
*Patients may have had more than one type of prior event.
†Includes patients with angina, percutaneous coronary intervention, coronary artery bypass grafting, or transient ischemic attack.
C/E, cost-effectiveness; MI, myocardial infarction; PAD, peripheral arterial disease.







0% annual discount rate $2,661 0.106 $25,139
5% annual discount rate $2,572 0.057 $44,891
Lost life-years due to in-trial cardiovascular deaths only* $2,607 0.051 $51,033
Lost life-years due to nonfatal events 50% above Saskatchewan estimates $2,607 0.082 $31,771
Lost life-years due to nonfatal events 50% below Saskatchewan estimates $2,607 0.061 $42,453
Clopidogrel costs 50% below average wholesale price $1,160 0.072 $16,176
Clopidogrel costs 50% above average wholesale price $4,054 0.072 $56,520
Cost of bleeding events 50% below base-case $2,549 0.072 $35,546
Cost of bleeding events 50% above base-case $2,661 0.072 $37,099
Hospitalization costs 50% below base-case $2,703 0.072 $37,680
Hospitalization costs 50% above base-case $2,511 0.072 $35,006
Post-acute care costs 50% below base-case $2,646 0.072 $36,899
Post-acute care costs 50% above base-case $2,567 0.072 $35,788
Including indirect costs from lost work productivity $2,593 0.072 $36,148
Including indirect costs from lost work productivity 50% below base-case $2,600 0.072 $36,246
Including indirect costs from lost work productivity 50% above base-case $2,586 0.072 $36,051
*Calculated for both clopidogrel + aspirin and aspirin alone patients.
C/E, cost-effectiveness.
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therapy compared with the “multiple risk factor” (i.e., primary
prevention) subgroup [4]. Moreover, the beneﬁts of clopidogrel
in this subgroup are consistent with previous studies demonstrat-
ing the incremental beneﬁt of clopidogrel to aspirin in both acute
and chronic treatment among patients with established CV
disease including the Clopidogrel Versus Aspirin in Patients at
Risk of Ischaemic Events, [23] Clopidogrel in Unstable Angina to
Prevent Recurrent Ischemic Events (CURE) [1], and Clopidogrel
for the Reduction of Events During Observation [3] trials.
Finally, because CHARISMA demonstrated excess mortality
among patients without documented CV disease, it is unlikely
that such patients would be prescribed clopidogrel for primary
prevention, making the issue of cost-effectiveness effectively
moot in this population.
The clinical decision to initiate dual antiplatelet therapy
requires an individualized assessment of potential beneﬁt versus
potential risk. Based on the results of CHARISMA, one can
project that treatment of 1000 patients with established CV
disease for 28 months would result in 10 fewer deaths, MIs, or
strokes although producing 11 additional moderate-to-severe
bleeding events. These values correspond to numbers needed to
treat (NNT) of 100 and a number needed to harm of 91. Ulti-
mately, the clinician must decide whether the relative importance
of these events—in terms of both clinical and economic
consequences—warrants the treatment for a given individual. If
the potential harm exceeds the beneﬁt for a particular patient,
dual antiplatelet therapy would not be advised regardless of
the cost-effectiveness. Our analysis—which uses quantitative
approaches to valuing both sets of consequences—suggests that
despite the additional risk, there may be sufﬁcient value in avoid-
ing serious CV events to justify both the additional risk and cost
of clopidogrel for the study population.
Moreover, there may be speciﬁc patient subgroups where
both the balance of risk and beneﬁt as well as cost-effectiveness
strongly favors extended dual antiplatelet therapy. For example,
a recent subgroup analysis of CHARISMA limited to subjects
with prior MI, ischemic stroke, or PAD demonstrated a 1.5%
absolute (17% relative reduction) in the risk of CV death, MI, or
stroke; this corresponds with an NNT of 67 to prevent an event
[5]. In addition to our main results, our subgroup analyses
demonstrate that adding clopidogrel to low-dose aspirin in
these high-risk patients (e.g., prior ischemic stroke, prior MI, or
PAD) was even more cost-effective than for overall cohort with
established CV disease. These ﬁndings reﬂect the fact that in
CHARISMA, such patients were at both higher risk of CV events
and derived a greater beneﬁt from dual antiplatelet therapy than
other trial participants. The fact that the ICER for clopidogrel for
these high-risk patient subgroups was <$22,000/LY gained in our
analysis (Table 4) suggests that these individuals may be ideal
populations for targeted application of dual antiplatelet therapy.
Comparison with Previous Studies
Overall, the cost-effectiveness of clopidogrel in the CHARISMA-
established CV disease population appears less favorable than in
prior studies of ACS and after PCI. For example, in the CURE
trial, the ICER for ~9 months of adding clopidogrel to aspirin
was ~$6000/LY in the ACS population and was even lower
among patients undergoing early PCI [15,21]. Using a decision
analytic model, investigators from Duke University found that
the ICER of extending the duration of clopidogrel from 1 to 12
months after PCI was $15,696/LY, compared with aspirin alone
[24]. The favorable cost-effectiveness of clopidogrel in ACS and
post-PCI settings is likely due to the greater absolute beneﬁt of
clopidogrel in these high-risk patient subsets. Combined with the
relatively brief administration of clopidogrel examined in these
trials, it is not surprising that the cost-effectiveness of adding
clopidogrel to aspirin would be more attractive under these con-
ditions than in CHARIMSA.
Our ﬁndings also appear to differ somewhat from previous
cost-effectiveness models that examined longer-term clopidogrel
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Figure 1 Cumulative distribution plot of the incremental cost-effectiveness
ratio for clopidogrel + aspirin versus aspirin alone based on bootstrap analysis
of primary Clopidogrel for High Atherothrombotic Risk and Ischemic Stabili-
zation, Management and Avoidance results. As indicated by the dashed lines,
70.6% of bootstrapped cost-effectiveness ratios were <$50,000 per life-year
gained and 87.4% were <$100,000 per life-year gained.







0% annual discount rate $2,699 0.106 $25,491
5% annual discount rate $2,609 0.057 $45,535
Lost life-years for cardiovascular deaths only $2,644 0.051 $51,758
Lost life-years (for nonfatal events) 50% above Saskatchewan estimates $2,644 0.082 $32,223
Lost life-years (for nonfatal events) 50% below Saskatchewan estimates $2,644 0.061 $43,057
Clopidogrel costs 50% below average wholesale price $1,197 0.072 $16,687
Clopidogrel costs 50% above average wholesale price $4,091 0.072 $57,042
Post-acute care costs 50% below base-case $2,678 0.072 $37,344
Post-acute care costs 50% above base-case $2,609 0.072 $36,376
Including indirect costs from lost work productivity $2,631 0.072 $36,680
C/E, cost-effectiveness.
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simulation model, Gaspoz et al. estimated an ICER of $61,000 to
120,000/QALY for lifetime dual antiplatelet therapy, depending
on the baseline assumptions of beneﬁt [25]. Schleinitz and
Heidenreich reported an ICER of $15,400/QALY for clopidogrel
added to aspirin for the ﬁrst year after ACS and $31,600/QALY
for the second year [26]. In a separate study, Schleinitz et al.
found that the use of clopidogrel alone compared with aspirin
alone appeared cost-effective after stroke ($31,200/QLY) and
PAD ($25,100/QALY) but not after MI [27].
Some of these differences may be explained by different
assumptions of beneﬁt; earlier cost-effectiveness studies had to
extrapolate the beneﬁts of clopidogrel from relatively short-term
ACS trials and apply them to longer-term therapy in a chronic
CV disease population [26,28]. Another reason may be that in
contrast to previous models [26,27], our study also accounted for
long-term survival beneﬁts associated with avoidance of nonfatal
MI or stroke in the short term. The strength of our study is that
it based the clinical outcomes of long-term clopidogrel obtained
from a randomized clinical trial speciﬁcally designed to examine
the population and treatment of interest, rather than estimated
from observational data or studies of short-term administration.
Although extrapolation beyond the trial duration was necessary
to estimate life expectancy, these projections were also based on
empirical observations from a large, relatively contemporary
data set (i.e., Saskatchewan) that was both matched to the char-
acteristics of the CHARISMA population and validated against
external benchmarks [12]. Finally, it is possible that our ﬁndings
are entirely consistent with previous models given the wide con-
ﬁdence limits of our results.
Implications for Treatment Duration
Although our study directly assessed the cost-effectiveness of
clopidogrel therapy provided for a median of 28 months, it is
important to recognize that our analysis assumed no further
treatment costs or beneﬁts beyond the time frame of the trial.
This approach is commonly used when performing a trial-based
economic analysis because the results of continued treatment
beyond the trial time frame are unknown [15,29]. Whether our
results can be readily extrapolated to more prolonged treatment
(with its attendant costs, beneﬁts, and side effects) depends on the
extent to which the beneﬁts observed in CHARISMA would be
expected to continue with more prolonged therapy. Speciﬁcally, if
the annual cost of therapy and absolute risk reduction beyond 28
months are similar to those observed in CHARISMA, the ICER
for additional years of therapy should be similar as in during the
trial. In CHARISMA, both the CV event rate in the aspirin alone
group and the relative risk reduction associated with clopidogrel
were nearly constant during the ﬁrst 2 years of follow-up (event
rate = 3.9% and 3.7%; relative risk reduction = 15.6% and
17.4%, respectively). The constant beneﬁt associated with clopi-
dogrel therapy over 2 years has also been observed in an obser-
vational study of patients who underwent PCI [30]. Although
there are limited data on the beneﬁts of clopidogrel after 28
months in patients with stable CV disease, the available data thus
suggest that the assumption of a constant absolute risk reduction
beyond the follow-up observed in the CHARISMA trial is
reasonable.
Study Limitations
As with any randomized clinical trial, our results apply most
directly to the trial population itself and should be extrapolated
with caution to other populations at lower or higher risk than
those enrolled in CHARISMA. In particular, extending our ﬁnd-
ings to patients at lower or higher risk of CV events than those
studied in CHARISMA would require both disease-simulation
modeling and additional assumptions. The approach of applying
US-derived unit costs to resource utilization across a wide range
of countries and health systems does not account for possible
differences in treatment practices of other countries, such as
different thresholds for hospitalization or use of procedures;
74% of patients in the CHARISMA trial with established CV
disease were enrolled in 31 countries outside of the United States.
Because there were only minimal cost offsets in the trial, however,
there should be little if any bias introduced by this approach.
Finally, the use of life expectancy projections derived from his-
torical Saskatchewan data may not be perfectly applicable to
current US practice and outcomes. To the extent that survival
with coronary heart disease have improved after 1995 [31],
however, it is likely that we have underestimated the life expect-
ancy gains associated with clopidogrel and thus overestimated
the resulting cost-effectiveness ratios.
Conclusions
For the prespeciﬁed subgroup of CHARISMA patients with
established CV disease, adding clopidogrel to aspirin for second-
ary prevention over 28 months of therapy appears to increase life
expectancy modestly at a cost commonly considered acceptable
within the US health-care system.
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